Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $128.2 million versus the consensus estimate of $40.47 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.